Home - Products - Others - Other Targets - Disomotide TFA 181477-43-0(free base)

Disomotide TFA 181477-43-0(free base)

CAS No.

Disomotide TFA 181477-43-0(free base) ( —— )

Catalog No. M22902 CAS No.

Disomotideis an oligopeptide for the treatment of melanoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Disomotide TFA 181477-43-0(free base)
  • Note
    Research use only, not for human use.
  • Brief Description
    Disomotideis an oligopeptide for the treatment of melanoma.
  • Description
    Disomotideis an oligopeptide for the treatment of melanoma.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    --
  • Formula Weight
    1149.24
  • Molecular Formula
    C49H75F3N10O16S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(O)C(F)(F)F.CC(C)[C@@H](C(O)=O)NC([C@H](CO)NC([C@H](CC1=CC=CC=C1)NC([C@H]2N(C([C@H](C(C)C)NC([C@H](CCC(N)=O)NC([C@H](CC(O)=O)NC([C@H](CCSC)NC([C@H]([C@@H](C)CC)N)=O)=O)=O)=O)=O)CCC2)=O)=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bayes M , Rabasseda X , Prous J R . Gateways to Clinical Trials[J]. methods & findings in experimental & clinical pharmacology, 2008, 30(4):313.
molnova catalog
related products
  • Clozic

    Clozic exhibits reversible anti-proliferative effects and can be used in studies about serving as a potential anti-arthritic agent.

  • 2,3,4,6-Tetra-o-acet...

    2,3,4,6-Tetra-o-acetyl-alpha-galactosylpyranosyl bromide is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

  • BMS-P5 free base

    BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.